Welcome to our dedicated page for CYAD news (Ticker: CYAD), a resource for investors and traders seeking the latest updates and insights on CYAD stock.
Celyad Oncology reports corporate, financial, and regulatory news as a biotechnology company focused primarily on unlocking the potential of its intellectual property. Company updates commonly address efforts to partner or out-license selected technologies, asset divestitures such as research-facility equipment and the C-CATHez catheter, and financial results that discuss operating expenses, cash resources, and capital needs.
News releases also cover Belgian transparency notifications, major shareholding thresholds, total voting rights, share counts, double voting rights, and warrants tied to the company’s Euronext-listed securities.
Celyad Oncology (CYAD) announces promising advancements in its allogeneic CAR T therapies, highlighting 2021's achievements and 2022 goals. The company aims to deliver key data from the KEYNOTE-B79 and IMMUNICY-1 clinical trials for CYAD-101 and CYAD-211 as they progress. The proprietary shRNA technology has been validated, offering a competitive edge, while a recent $32.5 million investment from Fortress Investment Group strengthens its financial position. Celyad ended 2021 with a treasury of €30 million ($34 million), ensuring funding into mid-2023.
Celyad Oncology SA announced a capital increase on 8 December 2021, issuing 6,500,000 new shares to Fortress Investment Group. This raised the total share capital to 78,584,224.33 EUR and resulted in a total of 22,593,956 shares, comprising 20,225,931 with single voting rights and 2,368,025 with double voting rights. The adjusted total diluted shares stand at 24,591,146, enhancing the voting rights to 26,959,171. This move complies with Belgian regulations on major shareholdings disclosures.
Celyad Oncology SA (Euronext & Nasdaq: CYAD) announced an issuance of 6,500,000 new shares on December 8, 2021, to Fortress Investment Group. This capital increase raises the company's share capital to 78,584,224.33 EUR with a total of 22,593,956 shares now outstanding. The decision aligns with Belgian law on the disclosure of major participations. Post-issuance, there are 20,225,931 shares with single voting rights and 2,368,025 shares with double voting rights. Additionally, the total diluted shares amount to 24,591,146.
Celyad Oncology SA (CYAD), a clinical-stage biotechnology firm, has announced its participation in the H.C. Wainwright BioConnect 2022 Conference, taking place from January 10 to January 13, 2022. CEO Filippo Petti will present on-demand starting January 10 at 7 a.m. ET. Celyad is focused on developing CAR T cell therapies for various cancers, and is progressing with both allogeneic and autologous therapy candidates. The company has received funding from the Walloon Region in Belgium to support its development programs.
Celyad Oncology SA (Euronext & Nasdaq: CYAD) announced a transparency notification on December 17, 2021, revealing that Tolefi SA and related individuals have crossed the 20% voting rights threshold, now holding 18.65% as of December 8, 2021. This notification signals a downward passive crossing of the threshold by persons acting in concert, emphasizing significant shareholder concentration which could influence company governance. The total number of voting rights is reported at 24,961,981.
Celyad Oncology SA (Euronext & Nasdaq: CYAD) announced a transparency notification regarding Tolefi SA and its affiliates crossing the 20% voting rights threshold. As of December 8, 2021, Tolefi SA holds 18.65% of the voting rights, down from the previous threshold. The notification details the individuals involved, including Serge Goblet and others, and highlights the number of voting rights before and after the transaction. The report emphasizes the company's ongoing focus on CAR T cell therapies.
Celyad Oncology announced the commencement of the KEYNOTE-B79 Phase 1b trial, evaluating CYAD-101 in combination with KEYTRUDA® for treating refractory metastatic colorectal cancer (mCRC) with microsatellite stable (MSS) disease. The first patient has been dosed, marking a significant step in assessing CYAD-101's potential. Preliminary data presented at the ASCO Gastrointestinal Cancers Symposium indicate promising results. The collaboration with MSD aims to explore the efficacy of this combination therapy, with initial results expected next year.
Celyad Oncology SA (Euronext & Nasdaq: CYAD) announced receipt of a transparency notification as of December 10, 2021, indicating that CFIP CLYD LLC, an affiliate of Fortress Investment Group, has crossed the 25% ownership threshold. This entity now holds 6,500,000 shares, representing 28.77% of Celyad's shares and 26.04% of voting rights as of December 8, 2021. The notification is a legal requirement following the acquisition of voting securities, affirming Fortress's significant stake in the company.
Celyad Oncology SA (CYAD) announced a transparency notification revealing that CFIP CLYD LLC, an affiliate of Fortress Investment Group, has acquired 28.77% of its shares, equating to 6,500,000 shares, as of December 8, 2021. This acquisition crossed the statutory threshold of 25%. Fortress Investment Group LLC indirectly controls CFIP CLYD LLC and has no controlling shareholder. The notification reflects substantial voting rights, now at 26.04%. This shift may impact shareholder dynamics and the overall governance of Celyad Oncology.
Celyad Oncology announced updates from its CYAD-02 and CYAD-211 clinical programs, showcasing the efficacy of its non-gene edited shRNA technology at the 63rd ASH Annual Meeting. The Phase 1 CYCLE-1 trial of CYAD-02 for r/r acute myeloid leukemia reported a favorable tolerability profile and promising initial clinical activity. In the Phase 1 IMMUNICY-1 trial of CYAD-211 for r/r multiple myeloma, early data showed good tolerability and some patients achieving partial responses. Upcoming enhancements in treatment regimens are planned to maximize clinical benefits.